Adult men with erectile dysfunction may be prescribed Fildena Super Active as an oral tablet to support erectile response during sexual stimulation. Its intended role is to improve penile blood flow…
Adult men with erectile dysfunction may be prescribed Fildena Super Active as an oral tablet to support erectile response during sexual stimulation. Its intended role is to improve penile blood flow when sexual arousal is present, rather than increase sexual desire.
Fildena Super Active is presented as an oral tablet for adult men with erectile dysfunction. Erectile dysfunction describes difficulty achieving or maintaining an erection sufficient for sexual activity. The treatment approach involves improving the vascular response in penile tissue while preserving the need for sexual stimulation.
Fildena Super Active belongs to the Fildena product family but is presented as a distinct formulation variant. The product supplied for this page is identified as a tablet, so it should be treated as an oral solid dosage form rather than a softgel capsule.
Fildena refers to the parent product name, while Fildena Super Active identifies the variant sold on this page. Differences between the two should be assessed through the confirmed strength, dosage form, and prescribed regimen, rather than by assuming that the names represent interchangeable products.
Fildena Super Active is intended for men whose erectile difficulty has been assessed as suitable for PDE5-inhibitor treatment. The clinical aim is improved erectile rigidity during sexual activity, not treatment of low libido, infertility, premature ejaculation, or urinary symptoms.
Sildenafil is a phosphodiesterase type 5 inhibitor, commonly abbreviated as a PDE5 inhibitor. Sildenafil citrate is the salt form used in oral pharmaceutical products. The substance acts on the enzyme system that regulates cyclic guanosine monophosphate, or cyclic GMP, in smooth muscle.
The clinically relevant indication is erectile dysfunction in adult men. Sildenafil does not directly create sexual desire, and it does not produce a reliable erection without sexual stimulation. Regulatory information from the FDA describes sildenafil as a treatment that supports the erectile response through enhanced nitric-oxide signalling [1].
The clinically relevant indication is erectile dysfunction in adult men. Fildena Super Active is intended for men whose erectile difficulty has been assessed as suitable for PDE5-inhibitor treatment. The clinical aim is improved erectile rigidity during sexual activity, not treatment of low libido, infertility, premature ejaculation, or urinary symptoms.
The selected regimen for Fildena Super Active must be confirmed with a healthcare professional before starting. The product should be taken orally with water and used only at the frequency agreed for the selected strength.
Key administration principles include:
The onset and duration of response vary with individual health, sexual stimulation, food intake, alcohol consumption, and other medicines. A large or high-fat meal can delay absorption of some oral sildenafil formulations. Excessive alcohol can reduce erectile responsiveness and increase dizziness or low blood pressure.
Fildena Super Active is used around sexual activity rather than as a continuous replacement therapy. If the planned dose is missed, skip it and use the next dose only according to the confirmed schedule. Taking extra tablets because the first dose was forgotten increases exposure without guaranteeing a better erection.
Do not combine sildenafil-containing treatment with tadalafil, vardenafil, avanafil, or another product intended to inhibit PDE5. Combining agents from the same pharmacological class can increase the risk of hypotension and adverse reactions.
Alpha-blockers, antihypertensives, and medicines that inhibit CYP3A4 can increase sildenafil exposure or lower blood pressure. Examples of clinically relevant CYP3A4 inhibitors include ritonavir, some macrolide antibiotics, and certain azole antifungals. A clinician should review the complete medicine list before confirming the regimen.
Grapefruit and grapefruit juice may affect CYP3A4 metabolism and can increase exposure in some people. Large amounts of alcohol can worsen dizziness and make erection less reliable, even when the tablet itself is taken correctly.
Fildena Super Active is not suitable for every man. Not for you if you use nitrates or have been advised to avoid sexual activity until cardiovascular assessment. The treatment should not be used when a PDE5 inhibitor would create an unsafe interaction or an unacceptable cardiovascular risk.
Sildenafil-based PDE5 treatment can cause headache, facial flushing, indigestion, nasal congestion, dizziness, and visual disturbances. These effects reflect vasodilation or the distribution of PDE5-related activity in other tissues. They may be mild and temporary, though persistent or severe symptoms require medical assessment.
Common practical effects include:
A sudden reduction or loss of vision is not an expected minor reaction. Chest pain, fainting, severe allergic swelling, or an erection lasting longer than four hours requires urgent medical care. The WHO identifies priapism and serious cardiovascular symptoms as events requiring prompt assessment in the context of erectile-dysfunction treatment [3].
Sexual stimulation activates nerves in penile tissue and promotes the release of nitric oxide. Nitric oxide stimulates production of cyclic GMP, which relaxes smooth muscle in the corpus cavernosum. This relaxation allows increased arterial blood flow and supports erection formation.
PDE5 breaks down cyclic GMP. Sildenafil inhibits PDE5, allowing cyclic GMP to remain active for longer when the nitric-oxide pathway has already been triggered. The result is improved physiological responsiveness to sexual stimulation.
The medicine does not increase libido independently. It cannot replace arousal, and it does not treat the psychological, hormonal, neurological, or relationship factors that may contribute to erectile difficulty. The European Medicines Agency and the MHRA describe PDE5 inhibition as a mechanism that facilitates erection in response to sexual stimulation [2].
Several avoidable errors can reduce benefit or increase risk:
The table compares pharmacological categories rather than commercial products. Exact onset and duration vary between individuals and formulations.
| Approach | Active mechanism | Practical distinction |
|---|---|---|
| Sildenafil-based treatment | PDE5 inhibition | Commonly used before planned sexual activity; response depends on stimulation |
| Tadalafil-based treatment | PDE5 inhibition with a longer pharmacological window | Often selected when a longer period of treatment flexibility is clinically appropriate |
| Non-drug erectile-function treatment | Addresses vascular, hormonal, psychological, or mechanical factors | May be needed when PDE5 inhibition is unsuitable or does not address the main cause |
Fildena Super Active should not be compared with another sildenafil product by brand name alone. The clinically relevant points are the active ingredient, strength, dosage form, timing, interactions, and the person’s cardiovascular history.
A man with predictable planned activity may prefer a shorter-window PDE5 approach. Someone seeking a longer treatment window may be assessed for a different active ingredient. Neither option is automatically better for every patient.
Sildenafil and tadalafil both inhibit PDE5, but their pharmacokinetic profiles differ. Sildenafil is generally used in connection with anticipated sexual activity, while tadalafil is associated with a longer period of pharmacological activity. The choice depends on response, tolerability, other medicines, cardiovascular status, and personal timing preferences.
In clinical practice, physicians usually assess erectile dysfunction as a symptom rather than an isolated event. Diabetes, hypertension, obesity, vascular disease, low testosterone, depression, anxiety, pelvic surgery, and medicine side effects may all contribute.
A clinician will usually want to know whether the difficulty is new, whether morning erections remain present, whether libido has changed, and whether symptoms occur in every situation. These details help distinguish vascular, hormonal, neurological, medication-related, and psychological contributors.
The main benefit of sildenafil-based treatment is its targeted effect on the erectile-response pathway. The main limitation is that it does not correct every cause of erectile dysfunction. It also cannot be used safely with nitrates, and it may be unsuitable when cardiovascular risk has not been assessed.
A useful clinical point is that repeated treatment failure does not always mean the medicine is ineffective. Incorrect timing, a heavy meal, too much alcohol, inadequate stimulation, and unrecognised diabetes can all interfere with the outcome.
Fildena Super Active is an oral tablet used around sexual activity, so a missed dose should not be replaced by taking extra tablets. The next dose should follow the regimen confirmed by a healthcare professional. FDA sildenafil prescribing information warns against exceeding the prescribed frequency because higher exposure can increase adverse effects without ensuring a stronger response. The HPRA also emphasises medicine-specific dosing and interaction assessment in patient safety information published before 2026.
Sildenafil-based treatment commonly begins to support erectile response within the period advised for oral use, provided sexual stimulation occurs. Food, alcohol, cardiovascular health, anxiety, and other medicines can alter the perceived timing. EMA product information from 2018 explains that the medicine facilitates erection only when sexual stimulation activates the nitric-oxide pathway. The response should not be judged solely by whether an erection appears without arousal.
Sildenafil does not normally require a taper because it is used intermittently and does not create physical dependence through continuous exposure. Stopping means the medicine will no longer support the PDE5 pathway during later sexual activity. The underlying erectile difficulty may return because the treatment does not remove conditions such as diabetes, vascular disease, or medicine-related sexual dysfunction. The FDA's 2014 prescribing information describes sildenafil as symptomatic treatment rather than a cure for the causes of erectile dysfunction.
Stop using the treatment and obtain urgent medical help for chest pain, fainting, severe breathlessness, sudden vision loss, sudden hearing loss, facial or throat swelling, or an erection lasting more than four hours. These symptoms can signal a serious cardiovascular, allergic, neurological, or urological event. WHO safety information from 2009 identifies prolonged erection as an emergency because delayed treatment can damage penile tissue. The HPRA advises urgent assessment for severe or unexpected reactions rather than taking another dose.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 4 reviews
I used the confirmed dose before a planned evening. The first attempt was disappointing because I had eaten a very heavy meal, but the next time the response was more noticeable after lighter food. I also had a mild headache that faded the same night.
28 Oct 2026The tablet helped with firmness after sexual stimulation, although I noticed facial warmth and some nasal congestion. I was taking blood-pressure treatment, so the regimen was confirmed before I started. I avoided alcohol because dizziness had been a problem with another medicine.
3 Nov 2026After several attempts I felt the treatment was inconsistent. A clinician reviewed my timing and medicines, and we found that I had been taking it after a large dinner. The response improved, but the headache remained troublesome on one occasion.
7 Oct 2026I stopped after developing chest discomfort during sexual activity. The symptom settled, but I sought urgent medical advice rather than taking another tablet. The treatment was not restarted until my cardiovascular situation had been assessed.
17 Oct 2026
